Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

By Craig R. Lee, J. Goldstein, J. Pieper. Pharmacogenetics (London), 2002

726 citations recorded by the source corpus.

Subfields: Oncology, Pharmacology, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/1e7e093a442496fb64b4984d81eee248486d2af0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Schwab
2. Ulrich M. Zanger

In Pharmacology

1. M. Schwab
2. Ulrich M. Zanger

Citations in the corpus

• Clinical Pharmacogenetics Implementation consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing (2011, neutral): “[55-60] high”
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “The major enzyme CYP2C9 accepts weakly acidic substances including the anticoagulant warfarin, the anticonvulsants phenytoin and valproic acid, the angiotensin receptor blockers candesartan and losartan, oral antidiabetics like glibenclamide and tolbutamide, and most nonsteroidal anti-inflammatory d”
• Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, neutral): “4% CYP2C9*3 homozygotes, respectively [67].”